Patents Assigned to Lennham Pharmaceuticals, Inc.
-
Publication number: 20240000799Abstract: Provided herein are compositions (e.g., pharmaceutical compositions) comprising deuterated testosterone, deuterated methyltestosterone, deuterated androstenedione, or derivatives thereof. The provided compositions and related methods may be useful for treating and/or preventing various diseases and conditions, such as hypogonadism, delay of growth and puberty, weight loss associated with HIV-associated wasting, vulvar dystrophies, micropenis, breast cancer, and sexual disorders.Type: ApplicationFiled: December 2, 2021Publication date: January 4, 2024Applicant: Lennham Pharmaceuticals, Inc.Inventors: Bradford C. Sippy, Benjamin D. Enerson
-
Publication number: 20230371555Abstract: Provided herein are compositions (e.g., pharmaceutical compositions, nutraceutical compositions, foods, beverages, cosmetic compositions, diet supplements) comprising deuterated caffeine. The provided compositions may be useful for treating and/or preventing various diseases and conditions, such as obesity, causing weight loss, increasing metabolic rate, reducing appetite, increasing energy expenditure, increasing urine output, increasing sodium excretion, reducing edema, a pain disorder, apnea, hypotension, an encephalopathy, a neurological or psychiatric disorder, and an inflammatory disorder.Type: ApplicationFiled: April 21, 2023Publication date: November 23, 2023Applicant: Lennham Pharmaceuticals, Inc.Inventor: Bradford C. Sippy
-
Publication number: 20230355632Abstract: Provided herein are compositions (e.g., pharmaceutical compositions, nutraceutical compositions, foods, beverages, cosmetic compositions, diet supplements) comprising deuterated paraxanthine. The provided compositions may be useful for treating and/or preventing various diseases and conditions, such as obesity, causing weight loss, increasing metabolic rate, reducing appetite, increasing energy expenditure, increasing urine output, increasing sodium excretion, reducing edema, a pain disorder, apnea, hypotension, an encephalopathy, a neurological or psychiatric disorder, and an inflammatory disorder.Type: ApplicationFiled: September 10, 2021Publication date: November 9, 2023Applicant: Lennham Pharmaceuticals, Inc.Inventor: Bradford C. Sippy
-
Patent number: 11666073Abstract: Provided herein are compositions (e.g., pharmaceutical compositions, nutraceutical compositions, foods, beverages, cosmetic compositions, diet supplements) comprising deuterated caffeine. The provided compositions may be useful for treating and/or preventing various diseases and conditions, such as obesity, causing weight loss, increasing metabolic rate, reducing appetite, increasing energy expenditure, increasing urine output, increasing sodium excretion, reducing edema, a pain disorder, apnea, hypotension, an encephalopathy, a neurological or psychiatric disorder, and an inflammatory disorder.Type: GrantFiled: June 12, 2020Date of Patent: June 6, 2023Assignee: Lennham Pharmaceuticals, Inc.Inventor: Bradford C. Sippy
-
Patent number: 11633371Abstract: The present disclosure provides compositions comprising deuterated forms of acetaminophen. When administered to human subjects, such compositions form less of the toxic metabolite NAPQI, and therefore are useful in methods of treating various diseases and conditions with a reduced risk of liver injury or other side effects associated with non-deuterated forms of acetaminophen.Type: GrantFiled: February 8, 2022Date of Patent: April 25, 2023Assignee: Lennham Pharmaceuticals, Inc.Inventor: Bradford C. Sippy
-
Publication number: 20230124138Abstract: Provided herein are compositions (e.g., pharmaceutical compositions) comprising deuterated testosterone, deuterated methyltestosterone, or derivatives thereof. The provided compositions and related methods may be useful for treating and/or preventing various diseases and conditions, such as hypogonadism, delay of growth and puberty, weight loss associated with HIV-associated wasting, vulvar dystrophies, micropenis, breast cancer, and sexual disorders.Type: ApplicationFiled: October 14, 2022Publication date: April 20, 2023Applicant: Lennham Pharmaceuticals, Inc.Inventors: Bradford C. Sippy, Benjamin D. Enerson
-
Patent number: 11547127Abstract: Provided herein are compositions (e.g., pharmaceutical compositions, nutraceutical compositions, foods, beverages, cosmetic compositions, diet supplements) comprising deuterated caffeine. The provided compositions may be useful for treating and/or preventing various diseases and conditions, such as obesity, causing weight loss, increasing metabolic rate, reducing appetite, increasing energy expenditure, increasing urine output, increasing sodium excretion, reducing edema, a pain disorder, apnea, hypotension, an encephalopathy, a neurological or psychiatric disorder, and an inflammatory disorder.Type: GrantFiled: March 31, 2022Date of Patent: January 10, 2023Assignee: Lennham Pharmaceuticals, Inc.Inventor: Bradford C. Sippy
-
Patent number: 11471469Abstract: Provided herein are compositions (e.g., pharmaceutical compositions) comprising deuterated testosterone, deuterated methyltestosterone, or derivatives thereof. The provided compositions and related methods may be useful for treating and/or preventing various diseases and conditions, such as hypogonadism, delay of growth and puberty, weight loss associated with HIV-associated wasting, vulvar dystrophies, micropenis, breast cancer, and sexual disorders.Type: GrantFiled: December 20, 2021Date of Patent: October 18, 2022Assignee: Lennham Pharmaceuticals, Inc.Inventors: Bradford C. Sippy, Benjamin D. Enerson
-
Publication number: 20220313630Abstract: The present disclosure provides compositions comprising deuterated forms of acetaminophen. When administered to human subjects, such compositions form less of the toxic metabolite NAPQI, and therefore are useful in methods of treating various diseases and conditions with a reduced risk of liver injury or other side effects associated with non-deuterated forms of acetaminophen.Type: ApplicationFiled: June 3, 2020Publication date: October 6, 2022Applicant: Lennham Pharmaceuticals, Inc.Inventor: Bradford C. Sippy
-
Publication number: 20220288083Abstract: Provided herein are compositions (e.g., pharmaceutical compositions, nutraceutical compositions, foods, beverages, cosmetic compositions, nutritional supplements) comprising d9-caffeine. The provided compositions may be useful for treating and/or preventing various diseases and conditions, such as obesity, causing weight loss, increasing metabolic rate, reducing appetite, increasing energy expenditure, decreasing daytime sleepiness, increasing urine output, increasing sodium excretion, reducing edema, a pain disorder, apnea, hypotension, an encephalopathy, a neurological or psychiatric disorder, and an inflammatory disorder.Type: ApplicationFiled: November 24, 2021Publication date: September 15, 2022Applicant: Lennham Pharmaceuticals, Inc.Inventor: Bradford C. Sippy
-
Publication number: 20220248720Abstract: Provided herein are compositions (e.g., pharmaceutical compositions, nutraceutical compositions, foods, beverages, cosmetic compositions, diet supplements) comprising deuterated caffeine. The provided compositions may be useful for treating and/or preventing various diseases and conditions, such as obesity, causing weight loss, increasing metabolic rate, reducing appetite, increasing energy expenditure, increasing urine output, increasing sodium excretion, reducing edema, a pain disorder, apnea, hypotension, an encephalopathy, a neurological or psychiatric disorder, and an inflammatory disorder.Type: ApplicationFiled: June 12, 2020Publication date: August 11, 2022Applicant: Lennham Pharmaceuticals, Inc.Inventor: Bradford C. Sippy
-
Publication number: 20220225642Abstract: Provided herein are compositions (e.g., pharmaceutical compositions, nutraceutical compositions, foods, beverages, cosmetic compositions, diet supplements) comprising deuterated caffeine. The provided compositions may be useful for treating and/or preventing various diseases and conditions, such as obesity, causing weight loss, increasing metabolic rate, reducing appetite, increasing energy expenditure, increasing urine output, increasing sodium excretion, reducing edema, a pain disorder, apnea, hypotension, an encephalopathy, a neurological or psychiatric disorder, and an inflammatory disorder.Type: ApplicationFiled: March 31, 2022Publication date: July 21, 2022Applicant: Lennham Pharmaceuticals, Inc.Inventor: Bradford C. Sippy
-
Publication number: 20220175796Abstract: Provided herein are compositions (e.g., pharmaceutical compositions) comprising deuterated testosterone, deuterated methyltestosterone, or derivatives thereof. The provided compositions and related methods may be useful for treating and/or preventing various diseases and conditions, such as hypogonadism, delay of growth and puberty, weight loss associated with HIV-associated wasting, vulvar dystrophies, micropenis, breast cancer, and sexual disorders.Type: ApplicationFiled: December 20, 2021Publication date: June 9, 2022Applicant: Lennham Pharmaceuticals, Inc.Inventors: Bradford C. Sippy, Benjamin D. Enerson
-
Patent number: 11344564Abstract: Provided herein are methods for the safe use of compositions comprising psilocin and prodrugs of psilocin for treating and/or preventing various diseases and conditions, such as mood or psychiatric disorders.Type: GrantFiled: December 17, 2021Date of Patent: May 31, 2022Assignee: Lennham Pharmaceuticals, Inc.Inventor: Bradford C. Sippy
-
Publication number: 20220160660Abstract: The present disclosure provides compositions comprising deuterated forms of acetaminophen. When administered to human subjects, such compositions form less of the toxic metabolite NAPQI, and therefore are useful in methods of treating various diseases and conditions with a reduced risk of liver injury or other side effects associated with non-deuterated forms of acetaminophen.Type: ApplicationFiled: February 8, 2022Publication date: May 26, 2022Applicant: Lennham Pharmaceuticals, Inc.Inventor: Bradford C. Sippy
-
Patent number: 11324762Abstract: Provided herein are pharmaceutical compositions comprising deuterated derivatives of psilocybin. The provided compositions may be useful for treating and/or preventing various diseases and conditions, such as mood or psychiatric disorders.Type: GrantFiled: August 19, 2021Date of Patent: May 10, 2022Assignee: Lennham Pharmaceuticals, Inc.Inventor: Bradford Sippy
-
Patent number: 11202785Abstract: Provided herein are compositions (e,g., pharmaceutical compositions) comprising deuterated testosterone, deuterated methyltestosterone, or derivatives thereof. The provided compositions and related methods may be useful for treating and/or preventing various diseases and conditions, such as hypogonadism, delay of growth and puberty, weight loss associated with HIV-associated wasting, vulvar dystrophies, micropenis, breast cancer, and sexual disorders.Type: GrantFiled: March 23, 2021Date of Patent: December 21, 2021Assignee: Lennham Pharmaceuticals, Inc.Inventors: Bradford C. Sippy, Benjamin D. Enerson
-
Publication number: 20210378266Abstract: Provided herein are compositions (e.g., pharmaceutical compositions, nutraceutical compositions, foods, beverages, cosmetic compositions, diet supplements) comprising deuterated caffeine. The provided compositions may be useful for treating and/or preventing various diseases and conditions, such as obesity, causing weight loss, increasing metabolic rate, reducing appetite, increasing energy expenditure, increasing urine output, increasing sodium excretion, reducing edema, a pain disorder, apnea, hypotension, an encephalopathy, a neurological or psychiatric disorder, and an inflammatory disorder.Type: ApplicationFiled: November 16, 2020Publication date: December 9, 2021Applicant: Lennham Pharmaceuticals, Inc.Inventor: Bradford C. Sippy
-
Patent number: 11000534Abstract: Provided herein are pharmaceutical compositions comprising deuterated derivatives of psilocybin. The provided compositions may be useful for treating and/or preventing various diseases and conditions, such as mood or psychiatric disorders.Type: GrantFiled: December 10, 2020Date of Patent: May 11, 2021Assignee: Lennham Pharmaceuticals, Inc.Inventor: Bradford Sippy
-
Publication number: 20210068429Abstract: Provided herein are compositions (e.g., pharmaceutical compositions, nutraceutical compositions, foods, beverages, cosmetic compositions, diet supplements) comprising deuterated caffeine. The provided compositions may be useful for treating and/or preventing various diseases and conditions, such as obesity, causing weight loss, increasing metabolic rate, reducing appetite, increasing energy expenditure, increasing urine output, increasing sodium excretion, reducing edema, a pain disorder, apnea, hypotension, an encephalopathy, a neurological or psychiatric disorder, and an inflammatory disorder.Type: ApplicationFiled: November 16, 2020Publication date: March 11, 2021Applicant: Lennham Pharmaceuticals, Inc.Inventor: Bradford C. Sippy